Data / Form D filings / Neurodyn Life Sciences Inc.
Neurodyn Life Sciences Inc.: Form D filings
Neurodyn Life Sciences Inc., a biotechnology company in Vancouver, British Columbia, Canada, filed 10 Form D notices with the SEC between 2013 and 2015. The latest, on November 2, 2015, reports $23,079 sold of a $23,079 offering to 1 investor.
Find out what Neurodyn Life Sciences Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 439 Helmcken Street, Vancouver, British Columbia, Canada, V6B 2
- Phone
- (604) 684-3323
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1568852
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2015 | New notice | $23,079 | $23,079 | $0 | 1 | Oct 19, 2015 | sec.gov |
| Oct 16, 2015 | New notice | $650,000 | $650,000 | $0 | 2 | Sep 30, 2015 | sec.gov |
| Mar 11, 2015 | Amendment | $1,408,880 | $1,408,880 | $0 | 7 | Dec 20, 2013 | sec.gov |
| Dec 8, 2014 | Amendment | $896,380 | $896,380 | $0 | 6 | Dec 20, 2013 | sec.gov |
| Sep 25, 2014 | New notice | $349,185 | $349,185 | $0 | 1 | Jan 7, 2014 | sec.gov |
| Sep 25, 2014 | New notice | $660,948 | $660,948 | $0 | 5 | Dec 20, 2013 | sec.gov |
| Jun 12, 2013 | New notice | $100,280 | $100,280 | $0 | 1 | May 28, 2013 | sec.gov |
| Apr 9, 2013 | New notice | $24,572 | $24,572 | $0 | 1 | Mar 30, 2013 | sec.gov |
| Feb 6, 2013 | New notice | $125,874 | $125,874 | $0 | 1 | Nov 28, 2012 | sec.gov |
| Feb 6, 2013 | New notice | $1,001,402 | $1,001,402 | $0 | 1 | Jan 23, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kenneth A. Cawkell | Executive Officer, Director | |
| James L. Mertz | Director | |
| Robert L. Cervelli | Director | |
| Madolyn L. Mertz | Director | |
| Richard L. Devries | Director | |
| Denis G. Kay | Executive Officer, Director |
Every Form D from the week of Nov 2, 2015 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Neurodyn Life Sciences Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.